Get the Stockscreener App
14.07
1.95%
-0.28
After Hours:
14.00
-0.07
-0.50%
Amylyx Pharmaceuticals Inc stock is traded at $14.07, with a volume of 680.19K.
It is down -1.95% in the last 24 hours and up +13.56% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$14.35
Open:
$14.47
24h Volume:
680.19K
Relative Volume:
0.44
Market Cap:
$1.55B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-5.628
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
+8.31%
1M Performance:
+13.56%
6M Performance:
+71.59%
1Y Performance:
+298.58%
1-Day Range:
$13.91
$14.77
1-Week Range:
$13.27
$15.11
52-Week Range:
$2.865
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.07 | 1.58B | -249.00K | -187.60M | -201.88M | -2.50 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.37 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.64 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.13 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Research Analysts Set Expectations for AMLX FY2029 Earnings - MarketBeat
FMR LLC's Strategic Acquisition of Amylyx Pharmaceuticals Inc Sh - GuruFocus
HC Wainwright Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price - MarketBeat
Amylyx stock price target raised to $28 from $20 at H.C. Wainwright By Investing.com - Investing.com South Africa
Amylyx stock price target raised to $28 from $20 at H.C. Wainwright - Investing.com India
Top Amylyx Executives Quietly Unload a Wave of Company Shares - TipRanks
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million - The Globe and Mail
Amylyx Pharmaceuticals, Inc. (AMLX): Investor Outlook With A 36% Potential Upside - DirectorsTalk Interviews
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Finviz
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHO - GuruFocus
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigation of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and Encourages Long-Term Amylyx Investors with Losses to Contact the Firm - ACCESS Newswire
Trend Report: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesWeekly Trade Recap & Community Trade Idea Sharing - baoquankhu1.vn
Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX) - Seeking Alpha
FY2030 Earnings Estimate for AMLX Issued By HC Wainwright - MarketBeat
Is Amylyx Pharmaceuticals Inc still a buy after recent gainsJuly 2025 Chart Watch & Entry Point Strategy Guides - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amylyx nominates AMX0318 as long-acting GLP-1 candidate for rare endocrine disorders - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4.5%What's Next? - MarketBeat
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside - Yahoo Finance
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 By Investing.com - Investing.com Nigeria
Amylyx Pharma Hits New HighDelivers Over 160% Gain In 7 Months - Nasdaq
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighTime to Buy? - MarketBeat
January 2027 Options Now Available For Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 - Investing.com
Amylyx pharma co-CEO Cohen sells $1.87m in shares By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 8.85% on Jan 20 - GuruFocus
Amylyx Pharmaceuticals (AMLX) Valuation After AMX0318 Rare Disease Pipeline Update - simplywall.st
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com Australia
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock By Investing.com - Investing.com India
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $1,850,862.87 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $27,300.42 in Stock - MarketBeat
Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading 11.7% HigherHere's What Happened - MarketBeat
EV Market: Is Amylyx Pharmaceuticals Inc stock a good pick for beginnersWeekly Stock Recap & Pattern Based Trade Signal System - baoquankhu1.vn
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders - Finviz
More Money In The Bank For Amylyx Pharmaceuticals Insiders Who Divested US$2.0m - 富途牛牛
Amylyx Pharmaceuticals Inc (AMLX) Trading 3.18% Higher on Jan 16 - GuruFocus
9 Overlooked Growth Stocks to Buy - Insider Monkey
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5%What's Next? - MarketBeat
Insider Trends: Will Amylyx Pharmaceuticals Inc. stock sustain high P E ratios2025 Trading Recap & Fast Moving Stock Watchlists - Bộ Nội Vụ
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) announces the selection of AMX0318 as development candidate for PBH and other rare diseases - MSN
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Finviz
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
10.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):